Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia
Table 2
Matrix metalloproteinases: MMP-2, MMP-3, MMP-9, and MMP-13 levels in maternal serum samples in both preeclamptic groups of women and in healthy controls.
MMP-2 (ng/mL)
MMP-3 (ng/mL)
MMP-9 (ng/mL)
MMP-13 (ng/mL)
The control group ()
195.30 ± 43.53 Median 189.95 (103.88–347.83)
29.23 ± 58.79 Median 16.749 (2.046–454.53)
1752.59 ± 901.54 Median 1605.75 (336.83–4569.2)
0.427 ± 0.228 Median 0.409 (0.014–1.047)
Statistical analysis, control-earlyPre
The group earlyPre ()
242.93 ± 68.64 Median 235.26 (136.88–466.90)
63.54 ± 71.58 Median 37.115 (13.65–314.14)
1450.12 ± 838.01 Median 1153.32 (243.68–3383.13)
0.590 ± 0.681 Median 0.407 (0.054–4.351)
Statistical analysis, earlyPre-latePre
The group latePre ()
234.39 ± 79.18 Median 219.17 (124.19–514.79)
27.91 ± 24.99 Median 18.04 (4.16–124.17)
1450.86 ± 1165.93 Median 1040.2 (325.07–6430.0)
0.482 ± 0.278 Median 0.385 (0.008–1,264)
Statistical analysis, control-latePre
Data presented as a mean ± SD. Statistical significance (); groups of studied pregnant women: control group: healthy normotensive pregnant women; earlyPre group: patients with pregnancy complicated by early-onset severe preeclampsia; latePre group: women with pregnancy complicated by late-onset severe preeclampsia.